Amgen, Inc. executives have been outspoken about the impact Medicare drug price negotiation under the Inflation Reduction Act (IRA) will have on the biopharmaceutical industry, but the pricing and reimbursement landscape in the US has become more challenging not just because of government policy shifts but also from increasingly difficult commercial payer negotiations.
Key Takeaways
-
Scrip spoke with Amgen SVP of US business operations Ian Thompson about how the company is managing its commercial portfolio in light of pricing and reimbursement pressures, such as the IRA.
-
Thompson noted that negotiating formulary placement with payers is taking longer, so patience is required in terms of seeing new launch products – including biosimilars – meet sales goals
Scrip spoke with Ian Thompson, Amgen’s senior vice president of US business operations, during the recent BIO International Convention about how the company is navigating rocky commercial terrain for its current and future therapeutics, including its potential obesity contender MariTide (maridebart
